The latest report by IMARC, titled “Contract Research Organization (CRO) Services Market Report by Type (Drug Discovery, Pre-Clinical, Clinical, and Others), Therapeutic Area (Oncology, Cardiology, Infectious Disease, Neurology, Immunological Disorders, Gastroenterology and Hepatology, and Others), End User (Pharmaceutical and Biotechnological Companies, Medical Device Companies, and Others), and Region 2025-2033”, finds that the global contract research organization (CRO) services market size reached USD 77.0 Billion in 2024. Contract research organization services or CRO services offer clinical management services to biotechnology, pharmaceutical and medical device producers. These organizations can either be large, international full-sized organizations or small, niche specialty groups that provide a device and drug research and development (R&D) services, such as preclinical research, drug discovery, and clinical research. In recent years, CRO services have gained momentum as they are economical and time-efficient and assist in accessing intricate knowledge of regulatory audits and requirements.
Global Contract Research Organization Services Market Trends:
One of the primary factors driving the market is the increasing technological advancements, due to which numerous companies outsource their research and development (R&D) activities to CROs. Additionally, the extensive utilization of CROs in the healthcare industry for medications, research, and drug delivery services is creating a positive market outlook. Other than this, the rising demand for better drugs and healthcare devices, on account of the increasing prevalence of chronic illnesses and growing patient population, is positively influencing the market growth. Furthermore, the rising cost of product development is providing a positive market outlook. Moreover, key players are investing extensively in research and development (R&D) activities to expand their consumer base. For instance, Covance Drug Development, a segment of Laboratory Corporation of America Holdings, bought Envigo RMS, LLC, a key provider of research models and services to improve the global research capabilities of Covance’s non-clinical drug development business. Looking forward, the market value is projected to reach USD 162.1 Billion by 2033, expanding at a CAGR of 8.6% during 2025-2033.
Market Summary:
- Based on the type, the market has been divided into drug discovery (target validation, lead identification, lead optimization, and others), pre-clinical, and clinical (phase I, phase II, phase III, phase IV trial services), and others.
- On the basis of the therapeutic area, the market has been segregated into oncology, cardiology, infectious disease, neurology, immunological disorders, gastroenterology and hepatology, and others.
- Based on the end user, the market has been segmented into pharmaceutical and biotechnological companies, medical device companies, and others.
- Region-wise, the market has been classified into North America (the United States and Canada), Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and Middle East and Africa.
- The competitive landscape of the market has also been analyzed, with some of the key players being Charles River Laboratories International Inc., Covance Inc. (Laboratory Corporation of America Holdings), ICON Clinical Research Limited, IQVIA Inc., Medpace Inc., Parexel International Corporation, PPD Inc., PRA Health Sciences Inc., SGS SA, Syneos Health Inc., and Wuxi AppTec Co. Limited.
Report Coverage:
Report Features |
Details |
Base Year of the Analysis |
2024 |
Historical Period |
2019-2024 |
Forecast Period |
2025-2033 |
Units |
Billion USD |
Segment Coverage |
Type, Therapeutic Area, End User, Region |
Region Covered |
Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered |
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered |
Charles River Laboratories International Inc., Covance Inc. (Laboratory Corporation of America Holdings), ICON Clinical Research Limited, IQVIA Inc., Medpace Inc., Parexel International Corporation, PPD Inc., PRA Health Sciences Inc., SGS SA, Syneos Health Inc., and WuXi AppTec Co. Limited |
Customization Scope |
10% Free Customization |
Post-Sale Analyst Support |
10-12 Weeks |
Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us:
IMARC Group
30 N Gould St, Ste
Sheridan, WY (Wyoming) 82801 USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800